Enhertu Improves Survival in People With HER2-Low MBC
A New Standard of Care? Enhertu Improves Survival in People With Metastatic HER2-Low Breast Cancer
June 6, 2022
Compared with doctors' choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer. Read more...